Solidseq Breast & Ovarian Cancer Panel Test
About Solidseq Breast & Ovarian Cancer Panel Test
| Field | Value |
|---|---|
| Also Known As | Solidseq Breast and Ovarian Cancer Panel; Tumour Tissue Breast and Ovarian Cancer Panel; NGS Tumour Profiling for Breast and Ovarian Cancer |
| Sample Type | FFPE Tissue Block |
| Fasting Required | No fasting required |
| Report Time | 30 days |
| Recommended For | Adults with a personal or family history of breast, ovarian, or related hereditary cancers; those with early-onset cancer or multiple primary cancers |
| Price | Starting at ₹36,000 |
What Is a Solidseq Breast & Ovarian Cancer Panel Test?
The Solidseq breast & ovarian cancer panel test is a specialised genetic test that analyses a large set of genes associated with hereditary breast, ovarian, and related cancers. It uses next-generation sequencing (NGS), a technology that reads millions of DNA segments simultaneously, to detect inherited mutations.
The test is prescribed for individuals with a strong personal or family history of cancer, early-onset diagnoses, or multiple primary cancers. A formalin-fixed, paraffin-embedded (FFPE) tissue block is used as the sample. This test is also known as the Solidseq breast and ovarian cancer panel, the tumour tissue breast and ovarian cancer panel, or NGS tumour profiling for breast and ovarian cancer.
What Does a Solidseq Breast & Ovarian Cancer Panel Test Measure?
The Solidseq breast & ovarian cancer panel test examines a broad set of genes linked to hereditary cancer syndromes. Each gene plays a specific role in DNA repair, tumour suppression, or cell cycle control. Below is a summary of the key gene groups tested and their relevance:
| Gene Group | Genes Included | Clinical Relevance |
|---|---|---|
| High-risk breast and ovarian cancer | BRCA1, BRCA2, TP53, PTEN, CDH1, STK11 | Strong association with hereditary breast, ovarian, and related cancers |
| Moderate-risk breast and ovarian cancer | PALB2, ATM, CHEK2, BARD1, BRIP1, RAD51C, RAD51D, NBN | Moderately elevated cancer risk; important for risk stratification |
| Lynch syndrome (mismatch repair) | MLH1, MSH2, MSH6, PMS2, PMS1, MLH3, MSH3, EPCAM | Increased risk of colorectal, endometrial, and ovarian cancers |
| DNA damage repair (Fanconi anaemia pathway) | FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, BRIP1, PALB2, RAD51C, SLX4, ERCC4, XRCC2 | Associated with Fanconi anaemia and elevated cancer susceptibility |
| Nucleotide excision repair | ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, DDB2, XPA, XPC | DNA repair deficiency syndromes |
| Homologous recombination repair | RAD50, RAD51C, RAD51D, MRE11A, RECQL, RECQL4, WRN, BLM | Genome stability; loss linked to cancer predisposition |
| RAS/MAPK signalling pathway | BRAF, KRAS, NRAS, HRAS, MAP2K1, MAP2K2, RAF1, RIT1, RRAS, RASA2, SPRED1, SHOC2, SOS1, SOS2, PTPN11, CBL, LZTR1 | Noonan and related syndromes; RAS-driven tumour growth |
| Tumour suppressor and cell cycle | RB1, CDKN2A, CDKN1B, CDKN1C, CDK4, TP53, PPM1D, EZH2, RUNX1 | Cell cycle regulation; loss of function linked to multiple cancers |
| Endocrine and neuroendocrine tumours | MEN1, RET, VHL, SDHB, SDHC, SDHD, SDHA, SDHAF2, TMEM127, MAX | Hereditary phaeochromocytoma, paraganglioma, and endocrine tumour syndromes |
| Neurofibromatosis and related syndromes | NF1, NF2, SMARCB1, LZTR1 | Benign and malignant nerve sheath tumours |
| Polyposis and gastrointestinal cancer | APC, MUTYH, SMAD4, BMPR1A, GREM1, STK11, AXIN2, GALNT12, NTHL1, POLD1, POLE, POLH | Colorectal and gastrointestinal cancer predisposition |
| Renal and other solid tumour genes | VHL, FLCN, PTEN, TSC1, TSC2, BAP1, PDGFRA, KIT, KITLG, MET, FH | Hereditary renal, mesenchymal, and stromal tumour risk |
| Haematologic cancer predisposition | RUNX1, ANKRD26, CEBPA, ETV6, GATA2, SRP72, IKZF1, PAX5, EZH2, DKC1, TERC, TERT, TINF2, POT1 | Familial leukaemia, bone marrow failure, and telomere biology disorders |
| Other hereditary cancer genes | ALK, DICER1, EXT1, EXT2, GPC3, HOXB13, MITF, NSD1, NSUN2, PHOX2B, PRF1, REST, RHBDF2, RPS20, SAMD9, SAMD9L, SBDS, EFL1, ELANE, FAM111B, CEP57, CD70, DIS3L2, DDX41, BAP1, PTCH1, SUFU, HNF1A, PRKAR1A | Diverse hereditary cancer syndromes and rare predisposition conditions |
Why Is a Solidseq Breast & Ovarian Cancer Panel Test Done?
This test helps identify whether a person carries inherited gene mutations that raise the risk of developing breast, ovarian, or other related cancers. Doctors may recommend it based on certain symptoms, personal history, or family history.
Common Symptoms That May Require This Test
The following personal or family history factors are the most common reasons a doctor orders this test:
- Personal diagnosis of breast or ovarian cancer, especially at a young age (before 50)
- Multiple family members diagnosed with breast, ovarian, or related cancers
- Male breast cancer in any family member
- Diagnosis of more than one primary cancer in the same individual
- Family history of a known hereditary cancer syndrome (such as Lynch syndrome or Li-Fraumeni syndrome)
- A known pathogenic mutation identified in a close family member
Conditions This Test Can Help Detect
This panel screens for a wide range of inherited cancer syndromes, including:
- Hereditary breast and ovarian cancer syndrome (BRCA1 and BRCA2 mutations)
- Lynch syndrome (caused by mutations in MLH1, MSH2, MSH6, or PMS2)
- Li-Fraumeni syndrome (TP53 mutations)
- Cowden syndrome (PTEN mutations)
- Hereditary diffuse gastric cancer (CDH1 mutations)
- Peutz-Jeghers syndrome (STK11 mutations)
- Neurofibromatosis type 1 and type 2 (NF1 and NF2 mutations)
- Familial adenomatous polyposis (APC mutations)
- Multiple endocrine neoplasia (MEN1 and RET mutations)
- Von Hippel-Lindau syndrome (VHL mutations)
- Fanconi anaemia and related DNA repair disorders
How to Prepare and What to Expect
This test requires a tissue sample rather than a blood draw. Preparation is straightforward, but providing complete background information is essential for accurate interpretation.
Do You Need to Fast?
No fasting is required for this test. You may eat and drink as usual before your visit. Always follow specific instructions provided by your doctor.
Practical Tips Before Your Test
Keep the following points in mind before your test:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Provide your cancer family history covering at least three generations, if possible
- Inform your doctor about any previous genetic tests you have had
- If you have had a recent blood transfusion or bone marrow transplant, let your doctor know, as this may affect sample quality
- Genetic counselling before the test is strongly recommended to help you understand what the results may mean
Step-by-Step Procedure
The Solidseq breast & ovarian cancer panel test procedure uses an FFPE tissue block. Here is what to expect:
- Your treating doctor or surgeon arranges for tumour tissue to be collected during a biopsy or surgical procedure.
- The tissue sample is fixed in formalin and embedded in paraffin wax to preserve it. This creates the FFPE tissue block.
- The block is packaged securely and transported to the laboratory at ambient temperature (18-28°C).
- At the laboratory, DNA is extracted from the tissue block.
- The extracted DNA is analysed using next-generation sequencing (NGS) to examine all genes in the panel.
- A specialist report is prepared and delivered within 30 days.
Factors That Can Affect Accuracy
Several factors can influence how reliable the test result is:
- Poor tissue preservation or insufficient tumour material in the block
- Recent blood transfusion or allogeneic stem cell transplantation, which can alter the DNA profile
- Mosaicism, where only some cells carry the mutation, reduces detection sensitivity
- Quality of DNA extracted from the FFPE block
- Prior chemotherapy or radiation treatment affecting DNA integrity
Understanding Your Solidseq Breast & Ovarian Cancer Panel Test Results
Results from this panel are complex and must always be reviewed with a qualified doctor or genetic counsellor. The table below explains the categories used in reporting:
| Result Category | Meaning |
|---|---|
| Negative (No pathogenic variant detected) | No known cancer-predisposing mutation was identified in the genes tested |
| Pathogenic Variant (PV) detected | A confirmed disease-causing mutation was found in one or more genes |
| Likely Pathogenic Variant (LPV) detected | A mutation with a high probability of being disease-causing was identified |
| Variant of Uncertain Significance (VUS) | A genetic change was found, but its clinical significance is currently unknown |
| Benign or Likely Benign | The variant found is not associated with increased cancer risk |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain circumstances can affect how results are interpreted:
- If you have had an allogeneic stem cell transplant, the DNA analysed may reflect the donor's profile rather than your own, which may alter result interpretation
- Haematologic (blood) cancers may require an alternative sample source, such as cultured skin cells (fibroblasts), for accurate germline testing
- Mosaicism, where the mutation is present in only a proportion of cells, may reduce the likelihood of detection
How to Maintain Healthy Levels
Because this is a genetic test rather than a biochemical measurement, "normal levels" do not apply. However, the following general steps are recommended after receiving results:
- Discuss all findings with a genetic counsellor and your oncologist to understand your personalised risk profile.
- If a pathogenic variant is identified, encourage first-degree relatives (parents, siblings, and children) to consider cascade testing.
- Follow any enhanced cancer surveillance protocols recommended by your specialist based on the specific gene mutation identified.
Lupin Diagnostics Solidseq Breast & Ovarian Cancer Panel Test Price
The Solidseq breast & ovarian cancer panel test cost starts at ₹36,000 at Lupin Diagnostics. This test requires a hospital visit or coordination through your treating doctor to submit a tissue block at the Lupin Diagnostics centre; home collection is not available for this test. The table below shows indicative prices:
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 36000 |
| Pune | 36000 |
| Bangalore | 36000 |
| Chennai | 36000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps for Solidseq breast & ovarian cancer panel test online booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time, or coordinate with your treating doctor to arrange submission of the FFPE tissue block.
- Receive your report via email or WhatsApp within 30 days.
Frequently Asked Questions
This panel is recommended for individuals with a strong personal or family history of breast, ovarian, or related cancers. It is also suitable for those diagnosed with cancer at a young age, people with multiple primary cancers, and individuals whose close family members carry a known pathogenic mutation. A doctor or genetic counsellor can advise whether testing is appropriate for your situation.
This test uses an FFPE tissue block, which is a preserved tissue sample from a previous biopsy or surgical procedure. This block is typically stored in a hospital or pathology archive. Your doctor will help arrange its retrieval and submission to the laboratory.
A VUS means a genetic change was detected in one of the genes tested, but current scientific evidence cannot confirm whether it raises cancer risk. This is not the same as a positive result. Your doctor or genetic counsellor will guide you on whether any follow-up is needed.
A negative result means no known pathogenic mutation was found in the genes covered by this panel. It does not eliminate all cancer risk. Cancer can still arise due to other genetic changes not covered by the panel, environmental factors, or spontaneous mutations. Regular screening as advised by your doctor remains important.
No. The Solidseq breast & ovarian cancer panel test identifies inherited genetic mutations that increase the risk of developing cancer in the future. It is not a cancer detection test. If cancer is suspected, separate diagnostic investigations are required.
At Lupin Diagnostics, results are typically reported within 30 days after the laboratory receives the sample. The report is delivered directly via email or WhatsApp.
Solidseq Breast & Ovarian Cancer Panel Test
